Comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma

Ended Project Grant Awarded Last action

Award ID
W81XWH2210346
Recipient
Awarding agency
Obligated
$2,247,531

Award facts

Assistance listing
12.420 Military Medical Research and Development
Completion date
Place of performance
Philadelphia, PA 19104, USA

Award details come from USAspending.gov.

About this award

The Department of the Army Medical Command awarded a $2,247,531 project grant to The Children's Hospital of Philadelphia through the Military Medical Research and Development program (CFDA 12.420) to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. The four-year project beginning September 1, 2022 will apply basic, applied, and advanced biomedical research approaches to transform pediatric cancer care and investigate medical solutions for childhood cancers through innovative immunological research. The Children's Hospital of Philadelphia Research Institute will leverage its expertise in pediatric oncology to evaluate the immune response in neuroblastoma patients undergoing various treatment regimens in an effort to improve outcomes and develop new therapeutic strategies for this high-risk childhood cancer.

Subawards

Subrecipient Amount Awarded
University Of Florida STATEMENT OF WORK University of Florida Arlene Naranjo, PhD, Co-Investigator Dr. Naranjo is the lead statistician for ANBL1531, the parent clinical trial upon… $32,332

Quick answers

Who received award W81XWH2210346?

W81XWH2210346 was awarded to The Children's Hospital Of Philadelphia by Medical Command (Department of the Army) on September 1, 2022.

How much is award W81XWH2210346 worth?

$2,247,531 has been obligated on W81XWH2210346.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award